Magnitude Biosciences: Revolutionising Research

Life Sciences consortium celebrate collective multi-million Biomedical Catalyst 2023 Innovate UK grant

Magnitude Biosciences awarded grant to accelerate the identification of compounds that could slow ageing or treat age-related diseases

AB Biotek works with Magnitude Biosciences to accelerate probiotic development

Pharmaceutical company Lundbeck in collaboration with Magnitude Biosciences on innovative new platform to test interventions for neurodegenerative disease

Magnitude Biosciences secures new investment to accelerate scaling of its specialist anti-ageing research services

Magnitude Biosciences Appoints New CEO Fozia Saleem to Drive Growth

SMER28 Extends Healthspan – Revealing a New Target for Ageing Therapeutics

Magnitude Biosciences CEO David Weinkove appointed new Chair of British Society for Research on Ageing

Frontiers in Aging: Applying C. elegans to industrial drug discovery

Magnitude Biosciences, Perfectus Biomed Group and University of Kent Project Funded by National Biofilms Innovation Centre for Tackling and Exploiting Biofilms

Research on ageing leader Magnitude Biosciences expands its project delivery team to meet increased demand

Magnitude Biosciences recognised in Developed in Durham as local success story

The worm angle on the taurine story: a route to the clinic by understanding mechanism

Magnitude Biosciences secures its second round of funding to support its pre-clinical research services

Magnitude Biosciences announces new hires to support continued growth

Magnitude Biosciences secures UK government Future Fund to expand its workforce.

Magnitude Biosciences’ new COVID-19 compatible laboratory is fully operational and we are ready to support your research